- Home
- MNR vs JANX Comparison
MNR vs JANX Comparison
Compare MNR & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNR
- JANX
- Stock Information
- Founded
- MNR 2017
- JANX 2017
- Country
- MNR United States
- JANX United States
- Employees
- MNR N/A
- JANX N/A
- Industry
- MNR
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- MNR
- JANX Health Care
- Exchange
- MNR Nasdaq
- JANX Nasdaq
- Market Cap
- MNR 1.7B
- JANX 1.5B
- IPO Year
- MNR 2023
- JANX 2021
- Fundamental
- Price
- MNR $15.07
- JANX $25.96
- Analyst Decision
- MNR Strong Buy
- JANX Strong Buy
- Analyst Count
- MNR 3
- JANX 8
- Target Price
- MNR $23.00
- JANX $90.63
- AVG Volume (30 Days)
- MNR 324.9K
- JANX 864.0K
- Earning Date
- MNR 08-12-2025
- JANX 08-06-2025
- Dividend Yield
- MNR 18.24%
- JANX N/A
- EPS Growth
- MNR 705.75
- JANX N/A
- EPS
- MNR 1.56
- JANX N/A
- Revenue
- MNR $941,846,000.00
- JANX $9,336,000.00
- Revenue This Year
- MNR $5.70
- JANX N/A
- Revenue Next Year
- MNR $4.36
- JANX $1,470.82
- P/E Ratio
- MNR $9.64
- JANX N/A
- Revenue Growth
- MNR 22.14
- JANX 28.12
- 52 Week Low
- MNR $12.40
- JANX $22.48
- 52 Week High
- MNR $20.94
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- MNR 57.59
- JANX 53.36
- Support Level
- MNR $14.42
- JANX $25.81
- Resistance Level
- MNR $14.89
- JANX $27.31
- Average True Range (ATR)
- MNR 0.37
- JANX 1.30
- MACD
- MNR 0.01
- JANX 0.08
- Stochastic Oscillator
- MNR 60.55
- JANX 45.02
About MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company. The company is focused on the acquisition, development and production of oil, natural gas, and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas, and the panhandle of Texas.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.